The endometrium and hormone replacement: Safety and bleeding

Hope S , Rees MCP . Why do British women start and stop hormone replacement therapy? J Br Meno Soc 1995; 1: 26-7.

Hope S , Wager E , Rees MCP . Survey of British women's views on the menopause and HRT. J Br Meno Soc 1998; 4: 33-36.

Salamone LM , Pressman AR , Seeley DG , Cauley JA . Estrogen replacement therapy. A survey of older women's attitudes. Arch Intern Med 1996; 156: 1293-7.

Stadberg E , Mattsson LA , Milsom I . Women's attitudes and knowledge about the climacteric period and its treatment. A Swedish population-based study. Maturitas 1997; 27: 109-16.

Ettinger B , Li DK , Klein R . Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: Comparison of cyclic versus continuous combined schedules. Fertil Steril 1998; 69: 865-9.

Grady D , Gebretsadik T , Kerlikowske K , Ernster V , Petitti D . Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995; 85; 304-313.

Archer DF , McIntyr-Seltman K , Wilborn WW , Cone F Endometrial morphology in asymptomatic premenopausal women. Am J Obstet Gynecol 1990; 65: 317-22.

Korhonen MO , Symons JP , Hyde BM , Rowan JP , Wilborn WH . Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausaland postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997; 176: 377-80.

Beresford SA , Weiss NS , Voigt LF , McKnight B . Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458-61.

Pike MC , Peters RK , Cozen W , Probst-Hensch NM , Felix JC , Wan PC , Mack TM . Estrogen-progestinreplacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 1110-6.

Weiderpass E , Adami HO , Baron JA , Magnusson C , Bergstrom R , Lindgren A , Correia N , Persson I . Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131-7.

Weiderpass E , Baron JA , Adami HO , Magnusson C , Lindgren A , Bergstrom R , Correia N , Persson I . Low-potency oestrogen and risk of endometrial cancer: A case-control study. Lancet 1999; 353: 1824-8.

Woodruff JD , Pickar JH . Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170: 1213-23.

The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275: 370-5.

Voigt L , Weiss N , Chu J , Daling J , McKnight B , van Belle G . Progestogen supplementation of exogeneous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-???

Brinton L , Hoover R . Estrogen replacement therapy and endometrial cancer: Unresolved issues. Obstet Gynecol 1993; 81: 265-71.

Sturdee DW , Barlow DH , Wells M , Ulrich LG , Gydesen H , Campbell M , O'Brien K , Vessey M . Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestogen replacement therapy? Lancet 1994; 343: 979-982.

Ettinger B , Selby J , Citron J , Vagessel A , Ettinger VM , Hendrickson MR . Cyclic hormone rep lacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693-700.

Hirvonen E , Salmi T , Puolakka J , Heikkinen J , Granfors E Can progestin be limited to every third month only in postmenopausal women taking oestrogen? Maturitas 1995; 21: 39-44.

Udoff L , Langenberg P. , Adashi EY . Combined continuous therapy: A critical review. Obstet Gynecol 1995; 86: 306-16.

Rees MCP , Barlow DH . Quantitation of hormone replacement induced withdrawal bleeds. Br J Obs Gynaecol 1991; 98: 106-7.

Sporrong T , Rybo G , Mattson LA , Vilbergson G , Crona N . An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy. Br J Obstet Gynaecol 1992; 99: 399-401.

Rees MCP , Brockie J , Holifield J , Sellers S , Naish C , Barlow D . Comparison of withdrawal bleeds with two cyclical hormone replacement preparations. 7th International Congress on the Menopause, 1993 Abstract Book, p 82.

Cole SK , Billewicz WZ , Thomson AM . Sources of variation in menstrual blood loss. J Obstet Gynaecol Br Commnw 1971; 78: 933-40.

Christiansen C , Riis BJ . Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins and bleeding pattern. Br J Obstet Gynaecol 1990; 97: 1087-92.

Stadberg E , Mattsson LA , Uvebrant M 17 beta-estradioland norethisterone acetate in low doses as continuous combined hormone rep lacement therapy. Maturitas 1996; 23: 31-9.

Al-Azzawi F , Wahab M , Habiba M , Akkad A , Mason T . Continuous combined hormone replacement therapy compared with tibolone. Obstet Gynecol 1999; 93: 258-64.

Archer DF , Pickar JH , Bottiglioni F , for the Menopause Study Group. Bleeding patterns in post menopausal taking continuous combined or sequential regimens of conjugated oestrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686-92.

Oosterbaan HP , van Buuren AH , Schram JH The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995; 21: 211-9.

Hammar M , Christau S , Nathorst-Boos J , Rud T , Garre K . A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904-11.

Davies GC , Huster WJ , Lu Y , Plouffe L Jr , Lakshmanan M . Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558-65.

Archer DF , Dorin MH , Heine W , Nanavati N , Arce JC Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol 1999; 94: 323-9.

Andersson K , Mattsson LA , Rybo G , Stadberg E Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963-7.

Rees MCP , Hague S , Oehler MK , Bicknell R . Regulation of endometrial angiogenesis. Climacteric 1999; 2: 52-58.

Veikkola T , VEGFs Alitalo K , receptors and angiogenesis. Semin Cancer Biol 1999; 3: 211-20.

Zhang L , Rees MCP , Bicknell R . The isolation and long term culture of normal human endometrial epithelium and stroma: Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progestogen challenge. J Cell Science 1995; 108: 323-331.

Zhang L , Scott PAE , Turley H , Leek R , Lewis CE , Gatter KC , Harris AL , MacKenzie IZ , Rees MCP , Bicknell R . Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: Expression of VEGF in the human endometrium. J Pathol 1998; 185: 402-8.

Grimwoood J , Bicknell R , Rees MCP . The isolation, characterization and culture of human decidual endothelium. Hum Reprod 1995; 10: 2142-48.

Brown NS , Bicknell R . Thymidine Phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998; 334: 1-8

Zhang L , MacKenzie IZ , Rees MCP , Bicknell R . Regulation of the expression of the angiogenic enzyme platelet derived endothelial cell growth factor/thymidine Phosphorylase in endometrial isolates by ovarian steroids and cytokines. Endocrinology 1997; 138: 4921-30.

Eto T , Kitamura K , Kato J . Biological and clinical roles of adrenomedullin in circulation control and cardiovascular diseases. Clin Exp Pharmacol Physiol 1999; 26: 371-80.

Zhao Y , Hague S , Manek S , Zhang L , Bicknell , Rees MCP . PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene 1998; 16: 409-15.